A 48-year-old woman from Delhi presents with a 6-month history of symmetrical polyarthritis affecting the PIP and MCP joints of both hands, morning stiffness lasting 2 hours, and constitutional symptoms. Laboratory investigations show RF 120 IU/mL (positive), anti-CCP 45 U/mL (positive), ESR 68 mm/h, and CRP 12 mg/dL. Plain radiographs of hands show no erosions. What is the most appropriate next step in management?

Explanation

## Management Strategy in Early RA **Key Point:** Early diagnosis and prompt initiation of DMARDs within 3 months of symptom onset is the cornerstone of RA management and significantly improves long-term outcomes and prevents joint damage. ### Why Methotrexate Is the Next Step **High-Yield:** The patient meets criteria for definite RA (RF+, anti-CCP+, symmetrical polyarthritis, elevated inflammatory markers). Despite the absence of radiographic erosions, she has seropositive disease with high inflammatory burden (ESR 68, CRP 12), indicating aggressive disease requiring immediate DMARD therapy. **Clinical Pearl:** The presence of anti-CCP antibodies is the strongest predictor of progressive, erosive disease and radiographic damage. Early DMARD initiation (within 3 months of symptom onset) is associated with remission rates of 40–50%, compared to <20% if delayed. ### Treatment Algorithm in Early RA ```mermaid flowchart TD A[Diagnosis of RA confirmed<br/>RF+/anti-CCP+ or<br/>clinical + imaging]:::outcome A --> B{Symptom duration<br/>< 3 months?}:::decision B -->|Yes| C[Initiate csDMARD<br/>Methotrexate preferred]:::action B -->|No| D[Still initiate DMARD<br/>but window of opportunity<br/>partially lost]:::action C --> E[Target: Low Disease Activity<br/>or Remission]:::outcome E --> F{Remission achieved<br/>at 3-6 months?}:::decision F -->|Yes| G[Continue DMARD<br/>+ low-dose prednisolone<br/>if needed]:::action F -->|No| H[Escalate: Add second csDMARD<br/>or switch to biologic]:::action ``` ### Why Other Options Are Incorrect | Option | Why It's Wrong | |--------|---------------| | **Prednisolone + NSAIDs alone** | Corticosteroids and NSAIDs do not modify disease course; they only provide symptomatic relief. Delaying DMARD therapy allows irreversible joint damage to accumulate. | | **MRI before DMARDs** | MRI is sensitive for early erosions but is NOT required to initiate therapy. Waiting for imaging delays treatment and worsens prognosis. Clinical diagnosis + serology are sufficient. | | **Biologic therapy immediately** | Biologics are reserved for inadequate response to csDMARDs or in specific high-risk scenarios (very high disease activity, multiple poor prognostic factors). First-line is methotrexate. | **Mnemonic:** **TREAT-2-REMISSION** — Treat early, treat-to-target (remission or low disease activity), target within 3 months of diagnosis. ### Key Management Principles 1. **Treat-to-Target Strategy:** Aim for remission (DAS28 <2.6) or low disease activity (DAS28 <3.2) by 3–6 months. 2. **Methotrexate as First-Line:** Oral or subcutaneous, starting 15 mg/week, titrated to 25 mg/week over 4–8 weeks. 3. **Bridge Therapy:** Low-dose prednisolone (≤7.5 mg/day) may be used temporarily while awaiting DMARD response (4–8 weeks). 4. **Monitoring:** FBC, LFTs, and renal function at baseline, then every 4–8 weeks during titration. [cite:Harrison 21e Ch 312]